Pyxis Oncology (PYXS) Long-Term Deferred Tax (2021 - 2023)

Pyxis Oncology (PYXS) has 3 years of Long-Term Deferred Tax data on file, last reported at $127.1 million in Q4 2023.

• On a quarterly basis, Long-Term Deferred Tax rose 106.75% year-over-year to $127.1 million in Q4 2023; TTM through Dec 2023 was $127.1 million, a 106.75% increase from a year earlier, with the FY2023 full-year figure at $127.1 million, up 106.75% from the prior year.
• Long-Term Deferred Tax for Q4 2023 stood at $127.1 million, up from $61.5 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for PYXS reached as high as $127.1 million in Q4 2023 and fell as low as $3.5 million in Q3 2021.
• Historically, Long-Term Deferred Tax has averaged $64.0 million across 3 years, with a median of $61.5 million in 2022.
• On a YoY basis, Long-Term Deferred Tax climbed as much as 106.75% in 2023 and fell as far as 106.75% in 2023.
• Year by year, Long-Term Deferred Tax stood at $3.5 million in 2021, then soared by 1656.24% to $61.5 million in 2022, then soared by 106.75% to $127.1 million in 2023.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $127.1 million in Q4 2023, $61.5 million in Q4 2022, and $3.5 million in Q3 2021.